Ann: PTX-100 trial advances following successful Phase 1b, page-271

Hahaha. None of us are experts, but we do our best.

I'm a bit confused by your links and assumptions.

The frist is a phase 1 trial in multiple myeloma patients with residual disease (1) and the second "This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with advanced solid tumors." was a phase 1 study in advanced solid tumors (2). I don't know where you have got 1260 patients from, as the multiple myeloma and the advanced solid tumor studies had 20 and 32 patients, respectively (below).





I think that if you are going to make comparisons to other research, you need to focus on the specific type of cancer. You may already know this, but if you don't - pembrolizumab is a PD1 inhibitor, most likely to respond in patients that have cancers that overexpress a surface protein called PD1. The inhibitor blocks the interaction between PD1 and PDL1 allowing the immune system to identify the cancer and kill it (where the term immunotherapy come from). The expression of PD1 and PDL1 is different for certain cancers, which is why I would encourage you to look at studies that specifically include T cell lymphoma patients. Here is another example of PD1/PDL1 inhibitor efficacy for T cell lymphoma (3).

Haha! I commend you for stepping up and having a go. Biotech is a very complex and fascinating area full of twists and turns. Name a CEO or MD that doesn't sound excited about their IP; I think it comes with the job description. I have some experience with research - https://www.researchgate.net/publication/344614977 - so I prefer to do the groundwork myself and come up with my own conclusions.

Thanks for the back and forth. Best of luck going forward.

1 https://clinicaltrials.gov/ct2/show/NCT02636010?term=MK-3475%3B+Anti-PD-1+Monoclonal+Antibody&draw=2&rank=7
2 https://clincancerres.aacrjournals.org/content/21/19/4286.long
3 https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01033-1